Champions Oncology
CSBR
25 hedge funds and large institutions have $49M invested in Champions Oncology in 2024 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 3 closing their positions.
2,033% more call options, than puts
Call options by funds: $192K | Put options by funds: $9K
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
74% more capital invested
Capital invested by funds: $28.2M → $49M (+$20.8M)
14% more funds holding
Funds holding: 22 → 25 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.18% less ownership
Funds ownership: 42.56% → 41.38% (-1.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$94.8K |
| 2 |
Morgan Stanley
New York
|
+$76K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$65K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$58K |
| 5 |
VF
Virtu Financial
New York
|
+$55.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAM
Tocqueville Asset Management
New York
|
-$485K |
| 2 |
Goldman Sachs
New York
|
-$236K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$6.23K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.59K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$569 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
UBS Group
Zurich,
Switzerland
| – | -$6.23K | -1,279 | Closed |
|
|
27
Simplex Trading
Chicago,
Illinois
| – | -$569 | -113 | Closed |
|
|
CAL
28
Capital Advisors Ltd
Shaker Heights,
Ohio
| – | +$242 | +48 | New |
|
CSBR Hedge Fund Activity: Q4 2024 in Review
25 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Champions Oncology (CSBR) for Q4 2024, worth a combined $49M — up 74% from $28.2M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CSBR positions and 3 closed out — a net gain of 3 holders — while 6 added to existing stakes and 3 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $94.8K. The largest seller was Tocqueville Asset Management, cutting an estimated $485K.
- 25 institutional investors held Champions Oncology (CSBR) as of Q4 2024, up from 22 in Q3 2024.
- Funds reported $49M of Champions Oncology stock for Q4 2024, up 74% quarter-over-quarter.
- 6 funds opened new Champions Oncology positions in Q4 2024 and 3 closed out, a net change of +3 holders.
- The largest Champions Oncology buyer in Q4 2024 was Renaissance Technologies, an estimated $94.8K added.
- The largest Champions Oncology seller in Q4 2024 was Tocqueville Asset Management, an estimated $485K sold.
Based on aggregated 13F filings for Q4 2024.